BRISBANE | Jotup

Who Says You Can’t Buy Elections?

Retrieved on:

Friday, March 22, 2024

Name, International, Republican, Marketing, Collection, Democrat, Auction

Set to be one of the most expensive political domains ever and is going under the hammer online on a major Australian and International auction platform Lloydsauctions.com.

Key Points:

Set to be one of the most expensive political domains ever and is going under the hammer online on a major Australian and International auction platform Lloydsauctions.com.
Considering $14.4 billion was spent by candidates in the 2020 U.S. Election, there should be enough left in the budget for a domain name.
Enquiries for domains in such demand as these include mainstream media companies, high level business operators, political party campaigners and influential celebrities or investors.
This rare domain name elections.com is going under the hammer Saturday 30th March from 8pm alongside a collection of other sought-after domain names.

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Wednesday, March 20, 2024

Quarter, Disease, Patient, UPCR, Clinical trial, Therapy, EGFR, Proteinuria, FDA, BLA, Hematuria, Pharmaceutical industry

“We believe atacicept 72-week data from the Phase 2b ORIGIN trial are consistent with a profile of true disease modification.

Key Points:

“We believe atacicept 72-week data from the Phase 2b ORIGIN trial are consistent with a profile of true disease modification.
The ORIGIN 2b results also provide us with even greater confidence in the ongoing ORIGIN Phase 3 trial, which continues to be on track with regard to enrollment,” stated Robert Brenner, M.D., Chief Medical Officer of Vera Therapeutics.
During the year ended December 31, 2023, net cash used in operating activities was $92.2 million, compared to $67.6 million for the same period last year.
Vera reported $160.7 million in cash, cash equivalents, and marketable securities as of December 31, 2023.

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on:

Tuesday, March 19, 2024

“2023 was a transformative year for Tempest.

Key Points:

“2023 was a transformative year for Tempest.
We announced strong positive randomized data showing the benefit of TPST-1120 combination therapy compared to standard-of-care in first-line liver cancer,” said Stephen Brady, president and chief executive officer of Tempest.
Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022.
Based on current cash and operating plan, Tempest expected to have sufficient resources to fund operations into the second quarter of 2025.

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Monday, March 18, 2024

Employment

BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.

Key Points:

BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.
The equity award was approved on March 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
The new non-executive employee received an option to purchase 3,500 shares of Annexon common stock.
The option carries a ten-year term and an exercise price per share equal to $6.69, which was the closing price of Annexon’s common stock on March 15, 2024, the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

Retrieved on:

Tuesday, March 12, 2024

HCC, Plasma, Head, Dicarboxylic acid, Immunotherapy, Patient, Standard of care, Cancer, Society, Bevacizumab, Pancreatic cancer, Therapy, SITC, FFA, Liver, Tempest, Medical imaging

BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2024 Spring Scientific Meeting highlighting preclinical data showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors.

Key Points:

BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2024 Spring Scientific Meeting highlighting preclinical data showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors.
“Data presented at the SITC Spring Scientific Meeting bolster our mechanistic understanding of PPARα blockade in cancer patients and reinforce a basis for the ongoing late-stage clinical development of TPST-1120,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest.
Clinical response and biomarker findings support that inhibition of PPARα may be an effective therapeutic strategy for the treatment of cancer.
These findings complement positive data reported in October 2023 from a global randomized phase 1b/2 study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC.

Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference

Retrieved on:

Monday, March 11, 2024

BRISBANE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases and their substrates, a new class of enzymes discovered in-house that are implicated in a broad variety of diseases, today announced an abstract titled “Unveiling of a Novel Therapeutic Antibody Targeting Nitrated Alpha Synuclein for the Treatment of Parkinson’s Disease” was featured in an oral presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference taking place in Lisbon, Portugal from March 5-9, 2024. The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies. Nitrase’s antibody demonstrated both high affinity and selectivity for nitrated synuclein, and it demonstrated the ability to significantly reduce PD progression in in vitro and in vivo PD models.

Key Points:

The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies.
A hallmark of PD pathology is the presence of Lewy Bodies and Lewy Neurites, which have been found to include an accumulation of nitrated α-synuclein.
It has been established in published studies that PD pathology spreads between brain regions along neural circuitry through extracellular aggregated α-synuclein.
Additionally, our antibody demonstrated superiority in a preclinical efficacy evaluation against the parental antibody of prasinezumab, which targets non-nitrated α-synuclein.

NOVONIX Releases Inaugural Sustainability Report

Retrieved on:

Thursday, March 7, 2024

Sustainability, RET, Biophysical environment, ESG, Health, Safety, ASX, Admiral, Workforce, Governance, USN, NVX, Renewable energy

BRISBANE, Australia, March 08, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced that it has released its inaugural Sustainability Report.

Key Points:

BRISBANE, Australia, March 08, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced that it has released its inaugural Sustainability Report.
NOVONIX’s Sustainability Report underscores the Company’s dedication to running a profitable, ethical, and sustainable business.
We are proud to publish our inaugural Sustainability Report to share our progress in promoting clean energy.”
The Sustainability Report presents the Company’s achievements to date, its plans moving forward, and the framework established to facilitate continuing progress.
To access NOVONIX’s inaugural Sustainability Report, please visit NOVONIX’s 2023 Sustainability Report on the Sustainability page of our website.

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Retrieved on:

Tuesday, March 5, 2024

Therapy, RCC, Poster, Renal cell carcinoma, AACR

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma (RCC) at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, CA.

Key Points:

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma (RCC) at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, CA.

Annature announces partnership with Diverger Limited to provide exclusive eSigning solution for advisers

Retrieved on:

Monday, March 4, 2024

ISO, Data communication, Partnership, Financial adviser

BRISBANE, Australia, March 04, 2024 (GLOBE NEWSWIRE) -- Australian eSigning innovator Annature today announced an exclusive partnership with Diverger Limited, a leading provider of integrated services to the wealth and accounting industries, to deliver integrated eSigning solutions to Diverger Limited’s ever-growing network of financial advisers and accountants.

Key Points:

BRISBANE, Australia, March 04, 2024 (GLOBE NEWSWIRE) -- Australian eSigning innovator Annature today announced an exclusive partnership with Diverger Limited, a leading provider of integrated services to the wealth and accounting industries, to deliver integrated eSigning solutions to Diverger Limited’s ever-growing network of financial advisers and accountants.
As part of the partnership, any advisers under Diverger Limited receive exclusive discounts and access to Annature’s industry-leading solutions when subscribing to the platform.
Diverger Limited will also make use of Annature’s integration with IRESS Xplan, a leading financial planning and advice software provider.
“We’re delighted to announce this partnership with Annature, and believe its market-leading solutions will be transformational for our advisers,” said Harry Wong, Senior Advice Technology Manager - Change and Comms at Diverger Limited.

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Retrieved on:

Wednesday, February 28, 2024

Therapy, Conference, Patient

BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will participate in the 44th Annual TD Cowen Health Care Conference, which is taking place from March 4th to 6th at the Marriott Copley Place in Boston, MA.

Key Points:

BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will participate in the 44th Annual TD Cowen Health Care Conference, which is taking place from March 4th to 6th at the Marriott Copley Place in Boston, MA.
IgAN Corporate Panel Discussion Details: